Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor

被引:1
|
作者
Teng, Yan [1 ]
Fan, Yibin [1 ]
Shang, Danying [1 ]
Tao, Xiaohua [1 ]
Sun, Dongsheng [2 ]
机构
[1] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Ctr Plast & Reconstruct Surg, Dept Dermatol,Peoples Hosp, Hangzhou 310014, Peoples R China
[2] Hangzhou Med Coll, Affiliated Peoples Hosp, Zhejiang Prov Peoples Hosp, Geriatr Med Ctr,Dept Geriatr Med, Hangzhou, Zhejiang, Peoples R China
关键词
alopecia universalis; sacubitril; alisartan; angiotensin receptor-neprilysin inhibitor;
D O I
10.2147/JIR.S427937
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Drug-induced alopecia areata is a rare adverse event wherein medications such as antimicrobials, anticonvulsants, and biologics, trigger the premature transition of actively growing hairs into the telogen phase. Herein, a unique case of alopecia universalis observed during a clinical trial involving sacubitril/alisartan, a novel angiotensin receptor-neprilysin inhibitor (ARNI) has been reported. This case contributes to the range of cutaneous reactions that might be observed in association with ARNI therapy.
引用
收藏
页码:3519 / 3522
页数:4
相关论文
共 50 条
  • [1] Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
    Dargad, Ramesh R.
    Prajapati, Mahesh R.
    Dargad, Rohit R.
    Parekh, Jai D.
    [J]. INDIAN HEART JOURNAL, 2018, 70 : S102 - S110
  • [2] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Boggarapu, Sreedevi
    Sunkara, Gangadhar
    [J]. CLINICAL PHARMACOKINETICS, 2017, 56 (12) : 1461 - 1478
  • [3] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    [J]. Clinical Pharmacokinetics, 2017, 56 : 1461 - 1478
  • [4] Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
    Ayalasomayajula, Surya
    Schuehly, Uwe
    Pal, Parasar
    Chen, Fabian
    Zhou, Wei
    Sunkara, Gangadhar
    Langenickel, Thomas H.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (05) : 926 - 936
  • [5] Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
    Sutanto, Henry
    Dobrev, Dobromir
    Heijman, Jordi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [6] Role of angiotensin receptor-neprilysin inhibitor in diabetic complications
    Liu, Ying
    Lu, Cun-Yu
    Zheng, Yi
    Zhang, Yu-Min
    Qian, Ling-Ling
    Li, Ku-Lin
    Tse, Gary
    Wang, Ru-Xing
    Liu, Tong
    [J]. WORLD JOURNAL OF DIABETES, 2024, 15 (05)
  • [7] Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
    Seki, Takunori
    Goto, Kenichi
    Kansui, Yasuo
    Ohtsubo, Toshio
    Matsumura, Kiyoshi
    Kitazono, Takanari
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (10):
  • [8] Is there a place for a dual angiotensin receptor-neprilysin inhibitor in the treatment of hypertension?
    Burnier, Michel
    [J]. JOURNAL OF HYPERTENSION, 2017, 35 (04) : 726 - 728
  • [9] Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
    Li, Kangbo
    Kratzmann, Victoria
    Dai, Mengjun
    Gatzke, Nora
    Rocic, Petra
    Bramlage, Peter
    Grisk, Olaf
    Lubomirov, Lubomir T.
    Hoffmeister, Meike
    Lauxmann, Martin A.
    Ritter, Oliver
    Buschmann, Eva
    Bader, Michael
    Persson, Anja Bondke
    Buschmann, Ivo
    Hillmeister, Philipp
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 9
  • [10] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor (vol 56, pg 1461, 2017)
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Boggarapu, Sreedevi
    Sunkara, Gangadhar
    [J]. CLINICAL PHARMACOKINETICS, 2018, 57 (01) : 105 - 123